Overview

An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability, multiple dose plasma pharmacokinetics (PK) of LNK-754 in male and female elderly volunteers after dosing with LNK-754 for 7 days and in subjects with mild Alzheimer's Disease after dosing with LNK-754 for 28 days.
Phase:
Phase 1
Details
Lead Sponsor:
Link Medicine Corporation